Lotte Biologics pledges $3b to beef up production at home
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
이 기사는 언론사에 의해 수정되어 본문과 댓글 내용이 다를 수 있습니다.
SAN FRANCISCO -- Lotte Biologics will invest around $3 billion by 2030 to build new CDMO plants in South Korea, Lotte Biologics CEO Richard Lee announced during the company’s presentation at the 41st JPMorgan Healthcare Conference held in San Francisco, Tuesday.
The investment will go toward building three plants, with a combined manufacturing capacity of 360,000 liters, 120,000 each, according to Lee. About $1 billion will be needed per plant, Lee estimated.
The company will start to build its first plant in the second half this year, finish construction by 2025, adopt good manufacturing practices in 2026 and start commercial operation in 2027.
It aims to have all three plants up and running by 2034.
Backed by their operations, the company could potentially post $3 billion in annual sales, with an operating profit rate of 35 percent, it said.
Lotte Biologics added that the company will build development-focused lab facilities nearby the manufacturing sites for startups and drug developers to use at no cost. It did not disclose where in Korea it would build the plants and lab facilities.
In addition to the new plants, Lotte Biologics will add a new facility for antibody drug conjugates (ADC) within its Syracuse plant.
Lee said the company will increase partnerships with ADC developers so it can become “the most trusted ADC conjugation site in the US.”
The ADC conjugation facility is expected to take some 15 months and is slated to begin operations next year.
Lotte Biologics is also looking into options to create a contract development organization (CDO) office in US-based biotech hubs, such as Kendall Square in Boston and San Francisco.
“We will improve our CDO capabilities, including cell line development, process development and analytical services,” Lee said.
In terms of an initial public offering, Lotte Biologics said the company plans to launch an IPO after completing the construction of the first plant.
By Shim Woo-hyun(ws@heraldcorp.com)
Copyright © 코리아헤럴드. 무단전재 및 재배포 금지.